Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?
Reviewed 21 sourcesPublished by PepVault
No study has tested sermorelin with a GLP-1, and no GLP-1 label names it. What the four labels say, what weight loss does to sermorelin, and blood sugar.

- Last reviewed
- Sources
- 21
- Questions
- 8
- Compounds
- 4
The short answer
No study has tested sermorelin with Ozempic, Wegovy, Mounjaro or Zepbound, and none of the four labels names it. Their interaction lines cover insulin, sulfonylureas and pills, and sermorelin is an injection. Sermorelin is not a GLP-1: it is a copy of the body's growth hormone-releasing hormone. Growth hormone can push blood sugar up, so whether to pair them is your prescriber's call.
Evidence: No human study of sermorelin with a GLP-1. The labels' own interaction lines, small human studies of sermorelin and of GHRH responses in obesity, two small uncontrolled GLP-1 trials on growth hormone, and one mouse and islet study.

Is sermorelin a GLP-1?
No. Sermorelin is the first 29 amino acids of growth hormone-releasing hormone (GHRH), the signal the brain sends to the pituitary to release growth hormone, and it is the shortest piece of that hormone with its full activity7. A GLP-1 copies a gut hormone that tells the pancreas to release insulin after a meal and tells the brain you are full. They are both peptides injected under the skin, which is where the mix-up starts, but they bind different receptors in different organs and do different jobs. The glossary has both: pepvault.app/glossary/ghrh and pepvault.app/glossary/glp-1.
| Question | Sermorelin | Semaglutide (Ozempic, Wegovy) | Tirzepatide (Mounjaro, Zepbound) |
|---|---|---|---|
| What it copies | GHRH, the brain's growth hormone signal7 | GLP-1, a gut hormone1 | GLP-1 and GIP, two gut hormones3 |
| What it acts on | The pituitary, which releases growth hormone7 | GLP-1 receptors1 | GLP-1 and GIP receptors3 |
| Time in the blood | About 4 minutes during an IV infusion in 10 healthy men12; the library's 11 to 12 minutes is the old Geref label's single-dose figure | About 1 week1 | About 5 days3 |
| How it is taken | Daily injection in the studies810 | Weekly injection; Wegovy also comes as a daily tablet12 | Weekly injection34 |
| US status, November 20, 2026 | Approved as Geref until its maker stopped selling it; approvals withdrawn in 2009, not for safety6 | Approved12 | Approved34 |
Because sermorelin left the US market, it has no current label on DailyMed. Its closest relative with one is tesamorelin (Egrifta), another GHRH analogue, so this guide uses tesamorelin's label where a GHRH label's words help5.

What do the Ozempic, Wegovy, Mounjaro and Zepbound labels say about other medicines?
Each GLP-1 label has two interaction lines, and none mentions sermorelin, growth hormone or any GHRH drug. Here are both lines from each label's current version on DailyMed, as of November 20, 2026.
| Label | The blood sugar line | The other-medicines line |
|---|---|---|
| Ozempic (version of June 2026)1 | Higher risk of low blood sugar, including severe; consider lowering the insulin or sulfonylurea dose when starting | Slows stomach emptying, so it may change how pills are absorbed; in its trials it did not affect absorption to any clinically relevant degree; use with caution |
| Wegovy (June 2026)2 | Lowers blood sugar and can cause lows; the risk rises with insulin or sulfonylureas; consider lowering their dose | Monitor pills taken alongside; with the semaglutide tablet, levothyroxine (thyroid hormone) exposure rose 33% |
| Mounjaro (August 2026)3 | Consider lowering the insulin or sulfonylurea dose when starting | Monitor pills with a narrow safe range, such as warfarin; switch from the contraceptive pill, or add a barrier method, for 4 weeks after starting and after each dose step |
| Zepbound (August 2026)4 | Lowers blood sugar; consider lowering the insulin or sulfonylurea dose when starting | The same warfarin and contraceptive-pill lines as Mounjaro |
| Egrifta WR, tesamorelin (July 2026)5 | Can cause glucose intolerance; check glucose before starting and periodically | Growth hormone may change how the liver clears drugs its CYP450 enzymes process (corticosteroids, sex steroids, seizure medicines, cyclosporine); people on steroid replacement for weak adrenal glands may need a higher dose |
Read against sermorelin, the GLP-1 lines mostly miss. The pill line exists because a GLP-1 slows the stomach, and sermorelin skips the stomach: it goes under the skin. The liver line on the tesamorelin label points at drugs the liver's CYP450 enzymes break down, and neither GLP-1 is one: the labels say semaglutide and tirzepatide are cut apart like other proteins and their fatty side chains burned off13. What remains is the line both drug families share, blood sugar, covered below. Each brand's page has the full label summary: pepvault.app/drugs/ozempic, pepvault.app/drugs/mounjaro and pepvault.app/drugs/zepbound, with all of them at pepvault.app/drugs.
Has any study combined sermorelin with a GLP-1?
No human study has. A PubMed search for sermorelin with semaglutide, tirzepatide, liraglutide, exenatide or GLP-1 returns no papers, and none of the 27 trials on ClinicalTrials.gov that give sermorelin, nor the 24 that give tesamorelin, adds a GLP-12021. The big GLP-1 trials, STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, tested the drug against placebo, not with a growth hormone peptide (pepvault.app/research/semaglutide-step-1-2021 and pepvault.app/research/tirzepatide-surmount-1-2022). Seller blogs cite cohorts of 112, 142 or 387 patients on the pair; none comes with authors, an abstract or a trial record we could find.
The nearest thing is a 2026 lab study. It paired MR-409, an experimental GHRH-receptor drug, with exendin-4, the molecule behind exenatide. In donated human pancreas islets, the pair raised insulin release and cut the death of insulin-making cells under inflammatory stress, on some markers more than either drug alone. In diabetic mice, each drug improved blood sugar, and the pair added nothing over either one18. That was in cells and mice, with neither sermorelin nor a weekly GLP-1, so it says little about a person taking both.
Does losing weight change how well sermorelin works?
It may make it work better: the pairing's most useful finding. Excess body fat blunts the pituitary's answer to GHRH. In one study, 12 people with marked obesity given the same IV dose of GHRH(1-29), the molecule sermorelin is, released growth hormone to a peak of 20 µg/L, against 44 µg/L in 8 lean volunteers13.
The blunting reverses with weight loss. In a 1990 study, obese adults lost from an average of 87.2 kg to 67.8 kg on an 8- to 12-week very-low-calorie diet, and their growth hormone response to GHRH, which had been markedly impaired, was significantly restored14. A 1988 study found the same rise after 6 weeks at 800 calories a day, which its authors credit to the weight lost, and after just 24 to 72 hours of fasting, which they credit to the missing food15. These studies used diets, not a GLP-1; whether the drug's weight loss does the same is untested. The library's timeline for sermorelin is at pepvault.app/peptides/sermorelin.
Does a GLP-1 change your growth hormone?
Possibly, and upward. In a 2023 analysis of two small trials in healthy adults, a single 10 µg injection of exenatide raised growth hormone in 8 of 10 people, peaking 60 to 120 minutes later, and 21 days of liraglutide 0.6 mg a day raised it too, in 10 people, with no change in IGF-1, the hormone growth hormone drives in the liver16. Neither trial had a placebo arm, and the authors say stress or the natural pulses of growth hormone could explain part of it16.
In mice the picture splits by sex: liraglutide lowered pulsed growth hormone in males and raised it in females, which the authors tie to how much weight each lost17. In people with type 2 diabetes on tirzepatide, the growth hormone surge that answers a deliberately induced low blood sugar was the same as on placebo19. None of this was measured with sermorelin on board.
What happens to blood sugar if you take both?
This is where the two pull in opposite directions. A GLP-1 lowers blood sugar. Growth hormone works against insulin, and the tesamorelin label shows it: over 26 weeks, 5% of people on tesamorelin reached an HbA1c of 6.5% or more (the diabetes line on the three-month blood sugar test), against 1% on placebo, and the label asks for a glucose check before starting and periodically after5.
Sermorelin's own trials saw no such shift. A year of nightly injections in 110 children left fasting glucose unchanged8. Two weeks at 1 mg twice daily in 10 older men did not change fasting glucose9, and 6 weeks at 2 mg nightly in 11 older men left the glucose and insulin response to a sugar drink unchanged10. In a 16-week trial of a close variant, insulin sensitivity improved in the men11. Those were small studies in people without diabetes, and none of them added a GLP-1.
When to get help If you have diabetes or take insulin or a sulfonylurea, talk to your prescriber before adding sermorelin, and get help for blood sugar lows that keep coming back or highs that will not come down135.
Why do people pair sermorelin with a GLP-1?
Mostly to hold on to muscle while the weight comes off. Part of the weight lost on a GLP-1 is lean mass (muscle, organs and water), and the guide at pepvault.app/guides/muscle-on-a-glp-1 has the trial figures. The sermorelin side of that hope is thin: in the 16-week trial of the close variant, lean body mass rose in the 9 men and not in the 10 women11, and 6 weeks of sermorelin in 11 older men changed neither muscle nor fat on a DEXA scan10. No study has measured lean mass with the two together.
Commonly reported: deeper sleep in the first weeks of sermorelin, a warm flush after the shot, and the hope of keeping strength while the GLP-1 takes appetite down; reports of the pair rest on personal accounts, not on any trial.
In its trials sermorelin was well tolerated; a brief facial flush and soreness where the shot went in were the effects reported most7. Its side-effect page is at pepvault.app/peptides/sermorelin/side-effects, and the doses the studies used are in the guide at pepvault.app/guides/sermorelin-dosage-in-studies.
How do you bring the question to your prescriber?
- Write down your GLP-1, its brand, the dose and the week you are on, since the labels' cautions apply most when starting and at each dose step34.
- Add every other medicine, including insulin, a sulfonylurea, thyroid hormone, warfarin, a steroid or the contraceptive pill: those are the drugs the labels name1235.
- Say that you are considering sermorelin, a GHRH analogue, and that no study has tested it with a GLP-1.
- Ask whether to check fasting glucose or HbA1c, and IGF-1, before and during, as the tesamorelin label does for glucose5.
- Ask whether each drug would get its own injection and its own schedule; the guide at pepvault.app/guides/mixing-peptides-in-one-syringe covers why separate injections are the tested default.
PepVault holds a weekly GLP-1 and a nightly sermorelin in one protocol, each with its own dose time and its own reminder, so the two schedules never blur. Set reminders in PepVault
Log side effects as they happen and add glucose, HbA1c and IGF-1 results in Bloodwork, then share the doctor's report at your next visit. Log it in PepVault
Sources
- OZEMPIC (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, set id adec4fd2-6858-4c99-91d4-531f5f2a2d79, version 20, effective June 1, 2026. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and tablet, prescribing information. Novo Nordisk. DailyMed, set id ee06186f-2aa3-4990-a760-757579d8f77b, version 19, effective June 18, 2026. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, set id d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version 40, effective August 27, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, set id 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, effective August 28, 2026. dailymed.nlm.nih.gov
- EGRIFTA WR (tesamorelin) for injection, prescribing information. Theratechnologies. DailyMed, set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, version 2, effective July 29, 2026. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness. Federal Register 78 FR 14095, March 4, 2013. federalregister.gov
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173
- Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996. PubMed 8772599
- Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992. PubMed 1379256
- Vittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. PubMed 9005976
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. PubMed 9141536
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. PubMed 7962295
- Castro RC et al. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects. Acta Endocrinol (Copenh). 1990. PubMed 2109445
- Tanaka K et al. Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism. 1990. PubMed 2118219
- Kelijman M, Frohman LA. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. J Clin Endocrinol Metab. 1988. PubMed 3127415
- Heinla K et al. GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers. Diabetes Ther. 2023. PubMed 36800161
- Almeida LF et al. Sex-dependent effects of liraglutide on growth hormone secretion occur independently of GLP-1 receptor expression in GHRH neurons. J Neuroendocrinol. 2026. PubMed 43045110
- Louzada RA et al. GHRH and GLP-1 receptor agonism promote human beta-cell survival and improve glucose homeostasis in diabetic mice. Endocrinology. 2026. PubMed 42811814
- Pieber TR et al. Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide. Front Endocrinol (Lausanne). 2025. PubMed 40964167
- U.S. National Library of Medicine. PubMed search: sermorelin AND (semaglutide OR tirzepatide OR liraglutide OR exenatide OR glucagon-like peptide OR GLP-1), 0 results, searched November 20, 2026. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. Studies with sermorelin (27) and tesamorelin (24) as an intervention; none adds a GLP-1. Searched November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.